Riaz, S., Din, S., Tareen, M., Tariq, F., Latif, Y., Siddiqi, S., Sultan, A., Mansoor, A. (2019). Genetic Polymorphism of CYP2C19 in Pakistani Population. Iranian Journal of Pharmaceutical Research, 18(2), 1097-1102. doi: 10.22037/ijpr.2019.1100644
Sana Riaz; Sadia Muhammad Din; Muhammad Usman Tareen; Fizza Tariq; Yusra Latif; Saima Siddiqi; Aneesa Sultan; Atika Mansoor. "Genetic Polymorphism of CYP2C19 in Pakistani Population". Iranian Journal of Pharmaceutical Research, 18, 2, 2019, 1097-1102. doi: 10.22037/ijpr.2019.1100644
Riaz, S., Din, S., Tareen, M., Tariq, F., Latif, Y., Siddiqi, S., Sultan, A., Mansoor, A. (2019). 'Genetic Polymorphism of CYP2C19 in Pakistani Population', Iranian Journal of Pharmaceutical Research, 18(2), pp. 1097-1102. doi: 10.22037/ijpr.2019.1100644
Riaz, S., Din, S., Tareen, M., Tariq, F., Latif, Y., Siddiqi, S., Sultan, A., Mansoor, A. Genetic Polymorphism of CYP2C19 in Pakistani Population. Iranian Journal of Pharmaceutical Research, 2019; 18(2): 1097-1102. doi: 10.22037/ijpr.2019.1100644
Genetic Polymorphism of CYP2C19 in Pakistani Population
1Institute of Biomedical and Genetic Engineering, 24 Mauve Area, G-9/1, Islamabad, Pakistan.
2Department of Biochemistry, Faculty of Biological Sciences, Quaid-i-Azam University, Islamabad, Pakistan.
Abstract
CYP2C19 polymorphism is associated with pretreatment drug response prediction, metabolism, and disposition. Pakistan consists of a population comprising of various ethnic groups residing in different regions of the country each claiming diverse ethnic origins. The identification of CYP450 genotypic composition of these populations is therefore necessary to avoid adverse drug reactions in these individuals. The main objective of the study was to investigate the prevalence of CYP2C19*2 and CYP2C19*17 alleles in these ethnic groups. The study was conducted on one thousand and twenty-eight (n = 1028) healthy volunteers from nine ethnic groups of Pakistan namely Brusho (n = 28), Hazara (n = 102), Kalash (n = 64), Pathan (n = 170), Punjabi (n = 218), Saraiki (n = 59), Brahui (n = 118), Parsi (n = 90), and Sindhi (n = 179). DNA was extracted from leukocytes and analyzed by allele specific amplification polymerase chain reaction (ASA-PCR). Multi allelic polymorphism of CYP2C19 led to four distinct phenotypes identified as extensive metabolizer (EM), poor metabolizer (PM), intermediate metabolizer (IM), and ultra-rapid metabolizer (UM). Over all, the percentage of predicted poor metabolizer allele was 29.0% compared to UM allele (23.70%).Among the studied groups, Saraiki and Brahui showed highest percentage of PM allele (40%, 36%) whereas Parsi and Hazara had highest percentage of UM allele (37% and 30% respectively). In conclusion, the high allele frequency of PM (CYP2C19*2 and *17) in Pakistani population led to the recommendation of a pre-treatment test to monitor drug response and dosage (personalized medicine) to avoid post-treatment adverse drug reactions.
Top